Genprex Inc (GNPX)

Has Ryan Confer been arrested yet?
CEO of Genprex?
IMO

They will never stop diluting and the product will never amount to anything?
Its just a scheme to raise money?
Started by the same crooks who schemed the previous product to steal all that money?
How the SEC allows this to happen is terrible?
Where is Nick Shirley?
Maybe she'd some light on this billion dollar health care scam?
IMO

Looks like they are still diluting.

Only stockholders who owned our common stock at the close of business on April 24, 2026, the record date for the Annual Meeting, are entitled to vote at the Annual Meeting. On this record date, there were 10,417,400 shares of our common stock outstanding and entitled to vote.

O/S increased to 9,044,856? 7 million more shares of fresh dilution?
Dilute then reverse split?
Always the same game?
Just theft?
IMO

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingApril 20, 2026 7:00 AM
PR Newswire (US)

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse StudiesREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, April 20, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators presented positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid, also referred to as Quar Oze), for the treatment of lung cancer.







"The identification of TROP2 and PTEN as potential biomarkers for primary resistance to REQORSA may provide invaluable insights for patient selection, enhancing our precision medicine strategy for our lung cancer clinical trials," said Ryan Confer, President and Chief Executive Officer at Genprex. "Furthermore, the demonstrated ability of REQORSA to induce apoptosis and decrease tumor volume in ALK-EML4 positive NSCLC cell lines and in vivo models, including those resistant to current ALK inhibitors such as alectinib, represents a potential opportunity for a future clinical trial. In addition, REQORSA's capacity to boost Natural Killer cell antitumor activity and immunity led to observed tumor suppression and even complete tumor elimination in preclinical studies. This demonstrates REQORSA's potential not only as a standalone agent, but also as a powerful adjunct therapy to re-sensitize resistant tumors and improve outcomes for a broad spectrum of lung cancer patients."The featured Genprex-supported abstracts and posters presented at AACR 2026:Title: "TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC)"
Session Category: Experimental and Molecular Therapeutics
Session Title: Mechanisms of Drug Resistance 1
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 16
Poster Board Number: 24
Abstract Presentation Number: 391In this study, researchers established models primarily resistant to TUSC2 gene therapy (REQORSA or Quar Oze) to find biomarkers indicative of TUSC2 gene therapy resistance in NSCLC cell lines, PDX-derived organoids (PDXOs), and patient-derived xenografts (PDXs). A panel of 10 NSCLC cell lines screened for TUSC2 sensitivity showed resistance in 50% of the cell lines, as assessed by annexin V staining and colony formation assays. Researchers evaluated TUSC2 sensitivity in 12 NSCLC PDXOs using ATP-based viability assays in 3D culture following TUSC2 or empty vector transfection. While some PDXOs were highly responsive to TUSC2 within 72 hours post-transfection, 50% of PDXOs exhibited primary resistance. TC314AR (Acquired Resistance) PDX tumors and xenograft models (A549AR, H1299AR, H23AR) were developed, grown in NSG mice, and then treated with TUSC2 gene therapy. 20-30% of tumors in every model showed resistance, with no significant reduction in size compared to the control tumors after treatment. Protein expression profiling using reverse-phase protein array (RPPA) analysis of 500 proteins showed distinct expression signatures, with several candidate biomarkers significantly altered in resistant cell lines and PDXOs. RPPA analysis of residual tumors from both the xenograft and PDX models revealed significant but model-specific alterations in protein expression between responders and non-responders. Comparative analyses across the three models showed low expression of TROP2 and high expression of PTEN as potential biomarkers of primary resistance. Overexpression of TROP2 in H1299 and H460 cells increased TUSC2-induced apoptosis. These findings suggest that TROP2 and PTEN may serve as biomarkers to predict TUSC2 response and guide therapeutic strategies in NSCLC.Title: "Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies"
Session Category: Experimental and Molecular Therapeutics
Session Title: RNA, Gene and Cell Therapies, and Enabling Assay Technologies
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 19
Poster Board Number: 12
Abstract Presentation Number: 469In this study, researchers evaluated TUSC2 expression in a range of ALK+ cell lines and patient-derived organoids (PDOs), both prior to and following exposure to quaratusugene ozeplasmid (Quar Oze). The findings show that Quar Oze-driven TUSC2 overexpression initiates a robust pro-apoptotic response in ALK-positive (ALK+) models, not only in cells that are sensitive but also with acquired resistance (generated in the lab) to the ALK inhibitor alectinib. This is evidenced by increased pro-apoptotic markers and lower cell viability when Quar Oze is used in combination with alectinib. To further assess the Quar Oze and alectinib combination, researchers tested it in two in vivo models: (1) an alectinib-sensitive model using subcutaneous injection of NCI-H2228 ALK+ cells into nude mice, and (2) an alectinib-resistant model using ALK167 PDX implants in NSG mice. Once tumors reached ~ 100 mm³, mice were randomized into four groups: vehicle control; Quar Oze alone (25 µg/mouse, IV, every three days); alectinib alone (0.5 mg/kg for sensitive or 15 mg/kg for resistant, oral, daily); and Quar Oze plus alectinib at the same doses. In the sensitive model, tumors in the alectinib-treated group shrank by 60%. Notably, treatment with Quar Oze alone, and particularly Quar Oze combined with alectinib, resulted in 79% tumor shrinkage (p value 0.0135 versus control), demonstrating a 23% improved outcome compared to alectinib alone. This suggests that Quar Oze might serve as a valuable adjunct therapy, especially for patients who have advanced disease and/or experience resistance to TKIs.In the resistant model, the Quar Oze and alectinib combination produced a synergistic effect, achieving the greatest tumor reduction and improved overall survival (p value 0.0001 versus control), further supporting the clinical potential of this therapeutic strategy in ALK+ NSCLC. Altogether, the in vitro and in vivo studies indicate that Quar Oze-mediated TUSC2 overexpression in ALK+ NSCLC effectively curtails tumor growth and proliferation via activation of apoptotic pathways, providing a compelling rationale for progressing toward a clinical trial.Title: "Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro"
Session Category: Immunology
Session Title: Immune Cell Biology and Tumor-Immune Crosstalk
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 8
Poster Board Number: 7
Abstract Presentation Number: 164TUSC2, located on chromosome 3p21.3, is frequently deleted in multiple human cancers, including NSCLC, small cell lung carcinoma (SCLC), mesothelioma, breast cancer and head-and-neck cancers. Loss of TUSC2 is associated with reduced survival and increased tumor aggressiveness. Although TUSC2 is known to suppress tumor cell proliferation and induce apoptosis, its regulatory role in the immune system—particularly in innate lymphoid populations—remains insufficiently defined. Building on prior work identifying TUSC2 as a mitochondrial protein involved in calcium regulation and immune modulation, researchers hypothesized that TUSC2 exerts antitumor effects in part by enhancing NK cell cytotoxicity.Tusc2 knockout (Tusc2 KO) and wild-type (Tusc2 WT) mice were challenged with syngeneic tumor cells (344SQ) and treated with TUSC2-expressing lipoparticles (quaratusugene ozeplasmid, Quar Oze). The therapeutic group received Quar Oze after tumor establishment starting at day 8 from cell line injection, while the prophylaxis group received Quar Oze before tumor establishment, starting 2 days before injection of cell lines. Control groups received empty lipoparticles. After three weeks from cell line injection, tumor volumes were assessed, and mice were euthanized for collection of tumors, spleens, and tumor-draining lymph nodes (TDLN). Immune cell phenotypes and cytotoxic markers were analyzed using flow cytometry.In vitro studies evaluated NK cell cytotoxic function following Quar Oze treatment by measuring CD107a degranulation and CellTrace Violet–based proliferation. In the therapeutic treatment group, 67% of Tusc2 KO mice and 33% of Tusc2 WT mice achieved complete tumor regression, with all remaining mice showing significant tumor reduction compared with controls. Prophylactic administration did not induce complete tumor clearance but consistently reduced tumor growth across all mice. Immune profiling of the tumor microenvironment revealed that Quar Oze robustly enhanced NK cell cytotoxicity, particularly increasing granzyme B and perforin expression. In vitro assays confirmed that TUSC2 restoration significantly increased NK cell degranulation and proliferation, supporting the in vivo findings.In conclusion, TUSC2 acts as a critical enhancer of innate antitumor immunity by boosting NK cell cytotoxic function. Therapeutic delivery of TUSC2 via Quar Oze suppresses tumor progression and, in many cases, drives complete tumor elimination. These results highlight TUSC2 as a potent immunomodulatory tumor suppressor and support its development as a dual-function therapeutic that directly targets tumor cells while also activating NK cell–mediated immunity.These AACR 2026 posters have been made available on Genprex's website here.About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.Genprex, Inc.
(877) 774-GNPX (4679)GNPX Investor Relations
investors@genprex.com GNPX Media Contact
Kalyn Dabbs
media@genprex.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting-302746321.htmlSOURCE Genprex, Inc.

Original: Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingMarch 18, 2026 7:00 AM
PR Newswire (US)

Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyREQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, March 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid, also referred to as Quar Oze), for the treatment of lung cancer.







"The selection of three distinct abstracts for presentation at the 2026 American Association for Cancer Research underscores the robust preclinical evidence supporting REQORSA's multi-faceted potential in the treatment of cancer," said Ryan Confer, President and Chief Executive Officer at Genprex. "These findings advance our understanding of TUSC2's therapeutic mechanisms and its impact on lung cancer. Additionally, the identification of TROP2 and PTEN as potential biomarkers of response to TUSC2 gene therapy in non-small cell lung cancer is a pivotal development, providing insights that could refine patient selection strategies and optimize the therapeutic efficacy of REQORSA in a clinical setting."The featured Genprex-supported posters to be presented at AACR 2026:Title: "TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC)"
Session Category: Experimental and Molecular Therapeutics
Session Title: Mechanisms of Drug Resistance 1
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 16
Poster Board Number: 24
Abstract Presentation Number: 391In this study, researchers established models primarily resistant to TUSC2 gene therapy (REQORSA or Quar Oze) to find biomarkers indicative of TUSC2 gene therapy resistance in NSCLC cell lines, PDX-derived organoids (PDXOs), and patient-derived xenografts (PDXs). A panel of 10 NSCLC cell lines screened for TUSC2 sensitivity showed resistance in 50% of the cell lines, as assessed by annexin V staining and colony formation assays. Researchers evaluated TUSC2 sensitivity in 12 NSCLC PDXOs using ATP-based viability assays in 3D culture following TUSC2 or empty vector transfection. While some PDXOs were highly responsive to TUSC2 within 72 hours post-transfection, 50% of PDXOs exhibited primary resistance. TC314AR (Acquired Resistance) PDX tumors and xenograft models (A549AR, H1299AR, H23AR) were developed, grown in NSG mice, and then treated with TUSC2 gene therapy. 20-30% of tumors in every model showed resistance, with no significant reduction in size compared to the control tumors after treatment. Protein expression profiling using reverse-phase protein array (RPPA) analysis of 500 proteins showed distinct expression signatures, with several candidate biomarkers significantly altered in resistant cell lines and PDXOs. RPPA analysis of residual tumors from both the xenograft and PDX models revealed significant but model-specific alterations in protein expression between responders and non-responders. Comparative analyses across the three models showed low expression of TROP2 and high expression of PTEN as potential biomarkers of primary resistance. Overexpression of TROP2 in H1299 and H460 cells increased TUSC2-induced apoptosis. These findings suggest that TROP2 and PTEN may serve as biomarkers to predict TUSC2 response and guide therapeutic strategies in NSCLC.Title: "Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies"
Session Category: Experimental and Molecular Therapeutics
Session Title: RNA, Gene and Cell Therapies, and Enabling Assay Technologies
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 19
Poster Board Number: 12
Abstract Presentation Number: 469In this study, researchers evaluated TUSC2 expression in a range of ALK+ cell lines and patient-derived organoids (PDOs), both prior to and following exposure to quaratusugene ozeplasmid (Quar Oze). The findings show that Quar Oze-driven TUSC2 overexpression initiates a robust pro-apoptotic response in ALK-positive (ALK+) models, not only in cells that are sensitive but also with acquired resistance (generated in the lab) to the ALK inhibitor, alectinib. This is evidenced by increased pro-apoptotic markers and lower cell viability when Quar Oze is used in combination with alectinib. To further assess the Quar Oze and alectinib combination, researchers tested it in two in vivo models: (1) an alectinib-sensitive model using subcutaneous injection of NCI-H2228 ALK+ cells into nude mice, and (2) an alectinib-resistant model using ALK167 PDX implants in NSG mice. Once tumors reached ~ 100 mm³, mice were randomized into four groups: vehicle control; Quar Oze alone (25 µg/mouse, IV, every three days); alectinib alone (0.5 mg/kg for sensitive or 15 mg/kg for resistant, oral, daily); and Quar Oze plus alectinib at the same doses. In the sensitive model, tumors in the alectinib-treated group shrank by 60%. Notably, treatment with Quar Oze alone, and particularly Quar Oze combined with alectinib, resulted in 79% tumor shrinkage (p value 0.0135 versus control), demonstrating a 23% improved outcome compared to alectinib alone. This suggests that Quar Oze might serve as a valuable adjunct therapy, especially for patients who have advanced disease and/or experience resistance to TKIs.In the resistant model, the Quar Oze and alectinib combination produced a synergistic effect, achieving the greatest tumor reduction and improved overall survival (p value 0.0001 versus control), further supporting the clinical potential of this therapeutic strategy in ALK+ NSCLC. Altogether, the in vitro and in vivo studies indicate that Quar Oze-mediated TUSC2 overexpression in ALK+ NSCLC effectively curtails tumor growth and proliferation via activation of apoptotic pathways, providing a compelling rationale for progressing toward a clinical trial.Title: "Restoring TUSC2 function boosts NK cell cytotoxicity and antitumor immunity in vivo and in vitro"
Session Category: Immunology
Session Title: Immune Cell Biology and Tumor-Immune Crosstalk
Session Date and Time: April 19, 2026 from 2-5 p.m. PT
Location: Poster Section 8
Poster Board Number: 7
Abstract Presentation Number: 164Tusc2 knockout (Tusc2 KO) and wild-type (Tusc2 WT) mice were challenged with syngeneic tumor cells (344SQ) and treated with TUSC2-expressing lipoparticles (quaratusugene ozeplasmid, Quar Oze). The therapeutic group received Quar Oze after tumor establishment starting at day 8 from cell line injection, while the prophylaxis group received Quar Oze before tumor establishment, starting 2 days before injection of cell lines. Control groups received empty lipoparticles. After three weeks from cell line injection, tumor volumes were assessed, and mice were euthanized for collection of tumors, spleens, and tumor-draining lymph nodes (TDLN). Immune cell phenotypes and cytotoxic markers were analyzed using flow cytometry. In vitro studies evaluated NK cell cytotoxic function following Quar Oze treatment by measuring CD107a degranulation and CellTrace Violet–based proliferation. In the therapeutic treatment group, 67% of Tusc2 KO mice and 33% of Tusc2 WT mice achieved complete tumor regression, with all remaining mice showing significant tumor reduction compared with controls. Prophylactic administration did not induce complete tumor clearance but consistently reduced tumor growth across all mice. Immune profiling of the tumor microenvironment revealed that Quar Oze robustly enhanced NK cell cytotoxicity, particularly increasing granzyme B and perforin expression. In vitro assays confirmed that TUSC2 restoration significantly increased NK cell degranulation and proliferation, supporting the in vivo findings.In conclusion, TUSC2 acts as a critical enhancer of innate antitumor immunity by boosting NK cell cytotoxic function. Therapeutic delivery of TUSC2 via Quar Oze suppresses tumor progression and, in many cases, drives complete tumor elimination. These results highlight TUSC2 as a potent immunomodulatory tumor suppressor and support its development as a dual-function therapeutic that directly targets tumor cells while also activating NK cell–mediated immunity.About TUSC2
TUSC2 is the tumor suppressor gene used in REQORSA (quaratusugene ozeplasmid or Quar Oze). REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.The aforementioned 2026 AACR posters will be available on Genprex's website following the completion of their live presentations.About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.Genprex, Inc.
(877) 774-GNPX (4679)GNPX Investor Relations
investors@genprex.com GNPX Media Contact
Kalyn Dabbs
media@genprex.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2026-aacr-annual-meeting-302716672.htmlSOURCE Genprex, Inc.

Original: Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Money diluting scam?

Over and over?

Rinse repeat steal?

IMO

GNPX.............................................p/m

Up today on patent news
https://www.genprex.com/2026/02/23/genprex-strengthens-intellectual-property-portfolio-with-japanese-and-eu-patents-for-reqorsa-gene-therapy-in-combination-with-immunotherapies-to-treat-cancer/

Q1 FDA meeting. Should get clarity on the path forward for Diabetes program.

They are taking products that previous failed tweaking them and running a dilution pyramid scheme off recycling them?

IMO

Just a heads up for those tracking the delisting risk: Genprex officially regained Nasdaq compliance as of Jan 9, 2026. > The company met the $2.5M stockholders' equity requirement, though they are under a one-year monitoring period until Jan 2027. This explains the heavy dilution/offerings in Oct/Nov—they were racing to save the listing.

Latest Milestones:

Diabetes (GPX-002): Positive NHP (primate) data just out. FDA meeting set for Q1 2026 to discuss human trials.

Cancer (Acclaim-1): Enrollment for the interim analysis (first 19 patients) is on track for 1H 2026.

High risk with the monitoring period, but the immediate threat of delisting is off the table for now. GLTA.

Gagged T/A last report 2.2M after another reverse split?

Last report in Novemeber 25?

Want to see theft?

Get the current O/S?

IMO

GNPX.................https://stockcharts.com/sc3/ui/?s=GNPX&p=w&b=5&g=0&id=p86431144783

We find out very soon if NASDAQ will rule that they are compliant with the equity standard.

Also as previously disclosed, the Nasdaq Hearings Panel (the “Panel”) of Nasdaq notified the Company on November 25, 2025, that the Panel had approved the Company’s request for an exception until December 31, 2025, to demonstrate long-term compliance with the Stockholders’ Equity Requirement.

As a result of proceeds raised from the Company’s previously disclosed registered direct offerings which closed on October 24, 2025 and October 29, 2025, proceeds raised from the Company’s usage of its “at the market” offering with H.C. Wainwright & Co., and the Company’s usage of its equity line of credit with Lincoln Park Capital, LLC, as of the date of this Current Report on Form 8-K, the Company believes it has stockholders’ equity in excess of the Stockholders’ Equity Requirement. However, the Panel has not yet determined whether the Company has regained compliance with the Stockholders’ Equity Requirement, and until the Panel determines that the Company is compliant with all applicable listing standards, there can be no assurance that the Common Stock will remain listed on the Nasdaq Capital Market.

Gagged T/A dilution machine?

Recycled peoduct?

Using Cancer research as a dilution mechanism will send you straight to hell?

Fraud?

IMO

There will be an interim analysis following the treatment of 19 patients in the Phase 2a portion of the Acclaim-1 study. We expect to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in the first half of 2026 and expect the interim analysis in the second half of 2026.

GNPX...............................................https://stockcharts.com/sc3/ui/?s=GNPX&p=W&b=5&g=0&id=p86431144783

Dilute reverse dilute dilute reverse dilute?

How much is too much higher theft off the thought of Cancer suffering?

What a peice of absolute garbage everyone within this company could be if they are mass diluting off the hopes of family members with cancer?

Ryan Confer you could be in handcuffs right now?

IMO

Watching for another entry...🥳

$2.99

$2.93

Been over $1 for a while. Have they announced NASDAQ compliance yet???

GNPX.......................................https://stockcharts.com/sc3/ui/?s=GNPX&p=W&b=5&g=0&id=p86431144783

GNPX..............................................p/m

Today's pr is the same as Oct 14, Exactly! It's criminal to pump like this.

GNPX, Bullshhhhit, exactly same PR released, repeating and repeating.

Does Ryan M Confer belong in prison?

Could he be the sleaziest greasy hairy suit to replace Bernie Maddoff of the list of con men?

IMO

Rinse and repeat, gag the T/A same old Genprex learning from Oncokix and Micheal Redman?

Cancer scams are the worst human beings on earth?

Reverse split will only lead to increasing the O/S with will lead to more dilution?

For what?

What is Ryan Confer using the money for?

Scam?
Fraud?
Deceit?
Theft?

Sanctions?

Lawsuit?

Ryan M Confer needs to address non existent shareholders?

Pyramid scheme?

Genprex?

IMO

GNPX...$14...🥳...Post Split...Float under 1 Million...

georgie18

Member Level
Re: georgie18 post# 4116

Monday, October 20, 2025 10:21:25 AM

Post#
4122
of 4122
GNPX...267...🥳...Open Gap filled here...

georgie18

Member Level
Re: georgie18 post# 702338

Wednesday, October 15, 2025 11:07:14 AM

Post#
702360
of 702734
GNPX...87...🥳...Off my .35 Alert...Took 1/2 off the table here...

georgie18

Member Level
Re: georgie18 post# 4104

Wednesday, October 15, 2025 9:47:36 AM

Post#
4110
of 4115
GNPX...5724....🥳...Off my .3521 Alert...

georgie18

Member Level
Re: georgie18 post# 702306

Wednesday, October 15, 2025 7:41:59 AM

Post#
702313
of 702337
GNPX...4398...🥳

georgie18

Member Level
Re: None

Wednesday, October 15, 2025 7:14:07 AM

Post#
4103
of 4103
GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics

GNPX...267...🥳...Open Gap filled here...

georgie18

Member Level
Re: georgie18 post# 702338

Wednesday, October 15, 2025 11:07:14 AM

Post#
702360
of 702734
GNPX...87...🥳...Off my .35 Alert...Took 1/2 off the table here...

georgie18

Member Level
Re: georgie18 post# 4104

Wednesday, October 15, 2025 9:47:36 AM

Post#
4110
of 4115
GNPX...5724....🥳...Off my .3521 Alert...

georgie18

Member Level
Re: georgie18 post# 702306

Wednesday, October 15, 2025 7:41:59 AM

Post#
702313
of 702337
GNPX...4398...🥳

georgie18

Member Level
Re: None

Wednesday, October 15, 2025 7:14:07 AM

Post#
4103
of 4103
GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics

Anyone who dilutes in the name of Cancer hopes should get a one way ticket to hell?



IMO

Lol pump and dump and more dump?

These slimy 3rd party con artist called this peice of S at 3 dollars?

Then came around claiming they called it at 30 cents?

Absolute losers?

IMO

Thanks...🥳...Have ups and downs like all of us do...

U looks on fire lately George!!! Congrats

Is it worth getting in this one anytime soon

GNPX...87...🥳...Off my .35 Alert...Took 1/2 off the table here...

georgie18

Member Level
Re: georgie18 post# 4104

Wednesday, October 15, 2025 9:47:36 AM

Post#
4110
of 4115
GNPX...5724....🥳...Off my .3521 Alert...

georgie18

Member Level
Re: georgie18 post# 702306

Wednesday, October 15, 2025 7:41:59 AM

Post#
702313
of 702337
GNPX...4398...🥳

georgie18

Member Level
Re: None

Wednesday, October 15, 2025 7:14:07 AM

Post#
4103
of 4103
GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics

who cares get in and get out - if you didnt make money here well i dont know what to tell ya lmfao

GNPX out of rest $1.05

.90 target one reached unload 80%

$1+ 😃

$GNPX 💹

$0.75+ 😃

$GNPX 💹

GNPX...5724....🥳...Off my .3521 Alert...

georgie18

Member Level
Re: georgie18 post# 702306

Wednesday, October 15, 2025 7:41:59 AM

Post#
702313
of 702337
GNPX...4398...🥳

georgie18

Member Level
Re: None

Wednesday, October 15, 2025 7:14:07 AM

Post#
4103
of 4103
GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics

$0.60+ 😃

$GNPX 💹

with this volume, it will surpass $1

Nice start 😃

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

https://investorshub.advfn.com/stock-market/NASDAQ/genprex-GNPX/stock-news/97000909/genprex-collaborators-to-present-positive-preclini

$GNPX 💹

They all are until their not...🥳

.52 + 102% see .90s and $1.10 up further nice net share accumulation yesterdaysSession: Poster Session CSession Date and Time: Saturday, October 25, 2025 from 12:30 – 4:00 p.m. ETGenprex https://edge.prnewswire.com/c/link/?t=0&l=en&o=4531642-1&h=3899054441&u=https%3A%2F%2Fwww.genprex.com%2F2024%2F10%2F24%2Fgenprex-announces-sponsored-research-agreement-with-the-university-of-michigan-rogel-cancer-center-and-lung-cancer-study-collaboration-with-alk-positive%2F&a=entered+into a Sponsored Research Agreement (SRA) with the University of Michigan Rogel Cancer Center in October 2024 to study TUSC2, the tumor suppressor gene used in REQORSA, in combination with ALK-inhibitors in ALK-EML4 positive translocated lung cancer. Also in October 2024, Genprex announced its collaboration with https://edge.prnewswire.com/c/link/?t=0&l=en&o=4531642-1&h=3078538918&u=https%3A%2F%2Falkpositive.org%2F&a=ALK+Positive, a non-profit patient-driven research organization dedicated to improving the life expectancy and quality of life for ALK-positive lung cancer patients, which shares in sponsoring this preclinical study.

GNPX...4398...🥳

georgie18

Member Level
Re: None

Wednesday, October 15, 2025 7:14:07 AM

Post#
4103
of 4103
GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics

GNPX...3521...🥳...https://finviz.com/news/191733/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-targets-and-cancer-therapeutics